141 studies found for:    psoriatic arthritis | psoriatic arthritis
Show Display Options
RSS Create an RSS feed from your search for:
psoriatic arthritis | psoriatic arthritis
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis
Conditions: Psoriatic Arthritis;   Work Productivity
Intervention:
2 Recruiting Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis
Conditions: Psoriatic Arthritis;   Psoriasis
Intervention:
3 Active, not recruiting AMG 827 in Subjects With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: AMG 827;   Drug: Placebo
4 Unknown  TIght COntrol of Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Intensive management or Tight control;   Drug: Standard management - Control group
5 Completed Phase II Study With CC-10004 in Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: CC-10004;   Drug: Matching Placebo
6 Active, not recruiting Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast 20mg;   Drug: Apremilast 30mg;   Drug: Placebo + 20 mg Apremilast;   Drug: Placebo + 30 mg Apremilast
7 Completed
Has Results
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention: Drug: etanercept
8 Completed Study of Psoriatic Arthritis
Conditions: Psoriasis;   Psoriatic Arthritis
Intervention:
9 Active, not recruiting PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast 20mg;   Drug: Apremilast 30mg;   Drug: Placebo + 20 mg Apremilast;   Drug: Placebo + 30 mg Apremilast
10 Active, not recruiting Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Conditions: Ankylosing Spondylitis;   Psoriatic Arthritis
Intervention:
11 Active, not recruiting PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast 20mg;   Drug: Apremilast 30mg;   Drug: Placebo + 20 mg Apremilast;   Drug: Placebo + 30 mg Apremilast
12 Completed Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice
Condition: Psoriatic Arthritis
Intervention:
13 Completed Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment
Conditions: Psoriasis;   Psoriatic Arthritis
Intervention:
14 Active, not recruiting Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast 20mg;   Drug: Apremilast 30mg;   Drug: Placebo + 20mg Apremilast;   Drug: Placebo + 30mg Apremilast
15 Recruiting Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
Condition: Psoriatic Arthritis
Interventions: Drug: Tofacitinib 5 mg BID;   Drug: Tofacitinib 10 mg BID;   Drug: Adalimumab;   Drug: Placebo
16 Completed Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention: Biological: AIN457A
17 Completed Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatment
Condition: Psoriatic Arthritis
Intervention:
18 Recruiting Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: 210 mg brodalumab;   Drug: 140 mg brodalumab;   Drug: Placebo
19 Recruiting Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
Condition: Psoriatic Arthritis
Interventions: Drug: Tofacitinib;   Other: Placebo
20 Recruiting Study of Efficacy, Safety and Effect on Radiographic Progession of Brodalumab in Subjects With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: 210 mg brodalumab;   Drug: 140 mg brodalumab;   Drug: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years